← boardnext 2028-05
CTNM
Contineum Therapeuticsdistress 2/10 · well-funded / low risk$14.48-2%today-12% from 52w high
Neurology 1Pain 1Respiratory 1
Lead: Multiple Sclerosis · target LPA1 · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$246M
Runway
4.3 yrs
Shares 1y
-18%
Price & events
+14.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+3.4%
1W
+21.6%
1M
+16.6%
3M
+11.5%
6M
+163.3%
1Y
-32.6%
2Y
—
5Y
-6.0%
All
Overview
- Market Cap
- $334.48M
- Volume
- 9.40K
- 52 Week Range
- $3.73 – $16.39
- Total Shares
- 23.10M
- Float Shares
- 27.59M
- Short %
- 6.57%
- % Held by Insiders
- 0.53%
- % Held by Institutions
- 94.11%
- RVOL
- 0.02x
- Beta
- 0.70
Pipeline stages · 1 programs
PIPE-791 Dose A, PIPE-791 Dose B
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-05 Estimated 50% readout ~2028-06-15 | Phase 2 | PIPE-791 Dose A, PIPE-791 Dose B | Idiopathic Pulmonary Fibrosis | — | recruiting |
| 2026-01-20 | Phase 1 | PIPE-791, Placebo | Chronic Osteoarthritis Pain, Chronic Low Back Pain | 43 | completed |
| 2025-07-14 | Phase 2 | PIPE-307 Dose A, PIPE-307 Dose B, Placebo | Relapsing Remitting Multiple Sclerosis | 182 | completed |
| 2025-06-04 | Phase 1 | PIPE-791 | Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Progressive, Multiple Sclerosis, Secondary Progressive, Healthy, Healthy Volunteers | 16 | completed |
Catalyst news & presentations · 5
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutPhase 1PIPE-791 · Topline data expected from Phase 1b chronic pain trial.SEC 8-K
- March 2026trial initiationsecondaryPhase 2PIPE-791 · Patient dosing initiated in global Phase 2 PROPEL-IPF trial.SEC 8-K
- November 20, 2025readoutPhase 2PIPE-307 · Topline data from VISTA trialSEC 8-K
- December 2024trial initiationsecondaryPhase 2PIPE-307 · Patient recruitment started for Phase 2 Moonlight-1 trial in MDD.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $22 (+54% upside) · 6 analysts
- 2026-05-14Morgan StanleyEqual-Weight
- 2026-03-06BairdOutperform
- 2026-01-08Morgan StanleyOverweight → Equal-Weight
- 2025-11-24BairdOutperform
- 2025-11-21RBC CapitalOutperform
- 2025-09-25Leerink PartnersOutperform
Competitors — LPA1
- none identified
Recent news
- 2026-07-18Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
- 2026-07-17Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update - Stock Titan
- 2026-07-17Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis - Kalkine
- 2026-07-17Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - Sahm
- 2026-07-15Liquidity Mapping Around (CTNM) Price Events - Stock Traders Daily
- 2026-07-10Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Canada
- 2026-07-10Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options - Stock Titan
- 2026-07-10Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.